04:13 AM EDT, 10/03/2024 (MT Newswires) -- Abivax ( ABVX ) said Thursday an interim analysis from its open-label maintenance study showed that patients with ulcerative colitis maintained clinical remission while taking its obefazimod drug at a reduced dose for up to two additional years.

Patients who initially took 50 milligrams of obefazimod daily were allowed to continue treatment at a reduced dose of 25 mg daily for up to five additional years, with data showing "maintenance of clinical remission at weeks 48 and 96," Abivax ( ABVX ) said.

The company said the treatment was well-tolerated, with a safety profile that was consistent with prior studies.